Challenge
The rising costs of healthcare and disease prevalence pose a major challenge to the availability, affordability and accessibility of high-quality care. Unserved disease markers, misdiagnosis and delayed detection remain a major challenge for health on both the individual and population level, as current lab-based diagnostics are still too slow, expensive and unfit for decentralised care.
Opportunity
The global point-of-care (POC) testing market is expected to reach $79B by 2030. For companies within the PhotonDelta ecosystem, the value capture lies in establishing high-volume biochip production for such regulated markets and positioning the Netherlands as a strategic supplier of next-generation diagnostic platforms.
Solution
The BioChip mission will focus on creating a photonic BioChip platform that enables ultra-sensitive, multi-biomarker diagnostics directly at the point of care.
The future of healthcare is faster, more precise, and closer to the patient. With photonic biochips, we enable ultra-sensitive diagnostics at the point of care. This solution strengthens the Netherlands’ position as a global supplier of next-generation diagnostic platforms. It’s about better outcomes, at lower cost, for millions of people.
Benefits
A photonic BioChip can reliably and cost-effectively detect multiple disease markers at very low concentrations, enabling faster and more reliable diagnostics in hospitals, GP practices and emergency rooms.
